Leon Garcia-Martinez,Anne Elisabeth Carvalho Jensen,Katie Olson Anderson,Benjamin H. Dutzar,John A. Latham,Brian R. Kovacevich,Jeffrey T. L. Smith,Mark Litton,Randall C. Schatzman
申请号：
US15276272
公开号：
US10117955B2
申请日:
2016.09.26
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.
